Chalazia development in multiple myeloma: A new complication associated with bortezomib therapy

Hematology Reports

Volumn 7, Issue 2, 2015, Pages 38-40

  Yun, Charles ^a   Mukhi, Nikhil ^a   Kremer, Valerie ^a   Shinder, Roman ^a   Verma, Vaibhav ^a   Batuman, Olcay ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Bortezomib; Chalazion; Eye disease; Multiple myeloma

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DEXAMETHASONE PLUS TOBRAMYCIN; DOXORUBICIN; DOXYCYCLINE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LENALIDOMIDE; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BACKACHE; BONE MARROW BIOPSY; BONE RADIOGRAPHY; CASE REPORT; CHALAZION; COMPRESSION THERAPY; CONJUNCTIVITIS; DIARRHEA; DRUG WITHDRAWAL; EYE SURGERY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMERUS FRACTURE; MALE; MIDDLE AGED; MONOSOMY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOLYSIS; SHOULDER PAIN; SURGICAL DRAINAGE; THORAX PAIN;

EID: 84931264821     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2015.5729     Document Type: Article

References (14)

1. Kyle RA, Rajkumar SV. An overview of the progress in the treatment of multiple myeloma. Expert Rev Hematol 2014;7:5-7.
2. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma Cells. Cancer Res 2001;61: 3071-6.
3. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed refractory myeloma. N Engl J Med 2003;348:2609-17.
4. Braunstein MJ, Scott SS, Scott CM, et al. Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101. J Oncol 2011;2011:232037.
5. Ghobirial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28: 1422-8.
6. Kanski JJ. Clinical ophthalmology: a systematic approach. 5th ed. Oxford: Butterworth-Heinemann Ltd; 1994.
7. Ballen PH. Inflammations of the lid. Int Ophthalmol Clin 1964;4:5-20.
8. Dhaliwal U, Arora VK, Singh N, et al. Cytopathology of chalazia. Diagn Cytopathol 2004;31:118.
9. Gilchrist H, Lee G. Management of chalazia in general practice. Aust Fam Physician 2009;38:311-4.
10. Grob SR, Jakobiec FA, Rashid A, et al. Chalazia associated with bortezomib therapy for multiple myeloma. Ophthalmology 2014;121:1845-7.
11. Gupta S, Silliman CG, Trump DL. Docetaxel-induced meibomian duct inflammation and blockage leading to chalazion formation. Prostate Cancer Prostatic Dis 2007;10:396-7.
12. Cunniffe MG, Medel-Jimenez R, Gonzalez- Candial M. Topical antiglaucoma treatment with prostaglandin analogues may precipitate meibomian gland disease. Ophthal Plast Reconstr Surg 2011;27:e128-9.
13. Mansour AM, Chan CC, Crawford MA, et al. Virus-induced chalazion. Eye (Lond.) 2006;20:242-6.
14. Solh M, Fisher RI, Goy A, et al. Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials. Leuk Lymphoma 2013;54: 2185-9.